| PE22.02 | MRI examination of cabotegravir long-acting formulation depot kinetics in healthy adult volunteers | E-poster | Pharmacology/PK and PD studies |
| PE22.03 | Impact of UGT induction by rifampin and rifabutin on cabotegravir long-acting pharmacokinetics for HIV pre-exposure prophylaxis (PrEP) using population pharmacokinetic modeling and simulation | E-poster | Pharmacology/PK and PD studies |
| OA10.01 | Planning for success: generating an early roadmap with global stakeholders for increasing access and uptake of new biomedical prevention products in resource-limited settings: The *Biomedical Prevention Implementation C*ollaborative (BioPIC) | Oral Abstract Session | Policy and advocacy |
| OA10.02 | Pathways to global access for novel HIV prevention technologies | Oral Abstract Session | Policy and advocacy |
| PE23.01 | Identifying regional disparities in access to HIV and sexual health resources for young men who have sex with men in the United States: The iREACH Study | E-poster | Policy and advocacy |
| PE23.02 | Adoption of WHO's HIV retesting policy for HIV-negative women during the breastfeeding period in 10 high HIV-burden African countries | E-poster | Policy and advocacy |
| PE23.03 | Ten years of the AVAC Advocacy Fellows Program: An evaluation | E-poster | Policy and advocacy |
| PE23.04 | Pathogen reduction (PR) as an alternative to donor deferral to mitigate the risk of transfusion-transmitted HIV | E-poster | Policy and advocacy |
| PE23.06LB | HIV prevention research and development funding trends 2000'2019: investment priorities to fund innovation in a challenging global health landscape | E-poster | Policy and advocacy |
| PE23.07LB | Planning for voluntary medical male circumcision (VMMC) program sustainability: generating evidence to support targeted transition planning in Zambia and Zimbabwe using the VMMC Transition Assessment Dashboard-VTAD | E-poster | Policy and advocacy |